Premaitha Health PLC (LON:NIPT)‘s stock had its “corporate” rating reaffirmed by equities researchers at FinnCap in a note issued to investors on Friday. They presently have a GBX 20 ($0.26) price objective on the stock. FinnCap’s target price would indicate a potential upside of 79.78% from the company’s previous close.

Separately, Panmure Gordon restated a “buy” rating and issued a GBX 24 ($0.31) target price on shares of Premaitha Health PLC in a research note on Monday, July 4th.

Premaitha Health PLC (LON:NIPT) opened at 11.125 on Friday. Premaitha Health PLC has a 1-year low of GBX 6.50 and a 1-year high of GBX 21.50. The firm’s market cap is GBX 23.15 million. The stock has a 50 day moving average price of GBX 10.44 and a 200 day moving average price of GBX 9.57.

Premaitha Health PLC Company Profile

Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques. The Company’s techniques are used for pre-natal screening (NIPT) and other clinical applications in the early detection, monitoring and treatment of disease.

Receive News & Stock Ratings for Premaitha Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health PLC and related stocks with our FREE daily email newsletter.